# STAR-221 (NCT05568095)

> A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05568095
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Arcus Biosciences, Inc.
- Conditions: Advanced Upper Gastrointestinal Tract Adenocarcinoma
- Interventions: Domvanalimab; Zimberelimab; Capecitabine; Fluorouracil; Leucovorin; Oxaliplatin; Nivolumab
- Enrollment: 1040
- Primary outcome: Overall survival

## Commentary we found

- X threads: 9
- YouTube: 8
- Podcasts: 6

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=star-221-nct05568095

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05568095", "email": "<work email>"}; the inbox owner confirms by the emailed link.